Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors
- 371 Downloads
Purpose of Review
The unleashing of the immune system in an effort to fight cancer has proven to be an incredible advance in the war on cancer. However that breakthrough has come with a price in the form of serious and potentially fatal immune-related adverse events (irAEs).
Rapid recognition and early intervention is imperative to avoid significant morbidity and mortality. Additionally, providers need to be aware that there are still new, rare, and long-term emerging irAEs that were not previously reported in clinical trials.
Because of the significant difference between irAEs and those caused by chemotherapy and/or targeted therapy, providers must have a thorough understanding of which events would be considered immune related and require treatment. This review will cover descriptions of the most common and uncommon but serious irAEs experienced by patients on immunotherapy, as well as management of these irAEs.
KeywordsCancer Immunotherapy Immune checkpoint inhibitors Immune-related adverse events
Compliance with Ethical Standards
Conflict of Interest
Lisa A. Kottschade has received research support through a grant from Bristol-Myers Squibb (paid to Mayo Clinic) and has served as a consultant for Genentech (compensation paid to Mayo Clinic).
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 8.Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616–22. https://doi.org/10.1200/JCO.2012.44.6112.PubMedCentralCrossRefPubMedGoogle Scholar
- 9.• Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017;JCO2016721167. Largest pooled analysis to date of irAEs from combination ICI therapy. Google Scholar
- 10.• Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211. Large review and meta-analysis of irAEs from anti-CTLA-4 therapy. PubMedCentralCrossRefPubMedGoogle Scholar
- 14.Co. M. Keytruda (pembrolizumab) for injection: Highlights of Prescribing Information. 2014, Accessed April 19, 2015 at http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf.
- 15.Di Giacomo AM, Danielli R, Guidoboni M, Calabro L, Carlucci D, Miracco C, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009;58(8):1297–306. https://doi.org/10.1007/s00262-008-0642-y.CrossRefPubMedGoogle Scholar
- 16.Ibrahim RA, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, et al., editors. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma 2011. J Clin Oncol. 2011.Google Scholar
- 21.O’Day S, Weber JS, Wolchok JD, Richards JM, Lorigan P, McDermott DF, et al. Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. J Clin Oncol. 2011; 29(15_suppl):8554.Google Scholar
- 27.Robert C, Schadendorf D, Messina M, Hodi FS, O’Day S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013;19(8):2232–9. https://doi.org/10.1158/078-0432.CCR-12-3080.CrossRefPubMedGoogle Scholar
- 30.Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64. https://doi.org/10.1016/S470-2045(09)70334-1.CrossRefPubMedGoogle Scholar
- 31.Zibelman M, Olszanski AJ. Full spectrum: efficacy and toxicity of immunotherapy in metastatic melanoma. J Natl Compr Cancer Netw. 2014; 12(suppl. 2): S-1–S-5.Google Scholar
- 32.• Abdel-Rahman O, Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther. 2017;17(4):387–94. Good overview of ocular toxicities which is a rare irAE. CrossRefPubMedGoogle Scholar
- 43.Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol. 2017:1. https://doi.org/10.1097/COC.0000000000000374.
- 46.Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, et al. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res. 2013;1(6):373–7. https://doi.org/10.1158/2326-6066.CIR-13-0092.PubMedCentralCrossRefPubMedGoogle Scholar
- 52.• Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21(2):371–81. Comprehensive review of endocrine toxicities from ICI therapy. This is an often difficult irAE to diagnose and manage and this article does a good job of defining these toxicities. PubMedCentralCrossRefPubMedGoogle Scholar
- 55.• Kottschade L, Brys A, Peikert T, Ryder M, Raffals L, Brewer J, et al. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res. 2016;26(5):469–80. Good comprehensive overview with algorithms of a multidisciplinary approach to manage irAEs for ICI therapy. CrossRefPubMedGoogle Scholar
- 56.Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100(8):4712–7. https://doi.org/10.1073/pnas.0830997100.PubMedCentralCrossRefPubMedGoogle Scholar
- 58.Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675–82. https://doi.org/10.1002/cncr.27969.CrossRefPubMedGoogle Scholar
- 62.Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother. 2017;66(1):25–32. https://doi.org/10.1007/s00262-016-1913-7.CrossRefPubMedGoogle Scholar